A detailed history of Walleye Capital LLC transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Walleye Capital LLC holds 48,800 shares of VKTX stock, worth $2.07 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
48,800
Previous 16,500 195.76%
Holding current value
$2.07 Million
Previous $874,000 253.43%
% of portfolio
0.01%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$49.84 - $70.47 $82,485 - $116,627
1,655 Added 26.76%
7,839 $496,000
Q2 2024

Aug 14, 2024

SELL
$47.39 - $80.2 $474,658 - $803,283
-10,016 Reduced 61.83%
6,184 $327,000
Q1 2024

May 15, 2024

BUY
$17.4 - $94.5 $281,880 - $1.53 Million
16,200 New
16,200 $1.33 Million
Q2 2023

Aug 14, 2023

BUY
$14.84 - $24.79 $566,695 - $946,655
38,187 Added 88.67%
81,251 $1.32 Million
Q1 2023

May 15, 2023

SELL
$8.08 - $17.33 $1.38 Million - $2.95 Million
-170,247 Reduced 79.81%
43,064 $717,000
Q4 2022

Feb 14, 2023

SELL
$2.72 - $9.4 $2.41 Million - $8.32 Million
-885,019 Reduced 80.58%
213,311 $2.01 Million
Q3 2022

Nov 14, 2022

BUY
$2.55 - $3.89 $2.05 Million - $3.12 Million
802,330 Added 271.06%
1,098,330 $2.99 Million
Q2 2022

Aug 08, 2022

BUY
$2.11 - $3.15 $462,052 - $689,793
218,982 Added 284.33%
296,000 $855,000
Q1 2022

May 16, 2022

BUY
$3.0 - $4.88 $231,054 - $375,847
77,018 New
77,018 $231,000
Q1 2020

May 15, 2020

SELL
$3.45 - $7.95 $78,439 - $180,751
-22,736 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$6.38 - $8.73 $145,055 - $198,485
22,736 New
22,736 $182,000
Q1 2019

May 15, 2019

SELL
$7.58 - $9.94 $133,210 - $174,685
-17,574 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$9.7 - $19.65 $170,467 - $345,329
17,574 New
17,574 $306,000

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $3.25B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Walleye Capital LLC Portfolio

Follow Walleye Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Capital LLC with notifications on news.